CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Moleculin Biotech, Inc. - MBRX CFD

    0.57
    1.79%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.05
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026235 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026235%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.004012 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.004012%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Key Stats
    Prev. Close* 0.56
    Open* 0.56
    1-Year Change* -58.52%
    Day's Range* 0.56 - 0.59
    52 wk Range 0.34-1.65
    Average Volume (10 days) 242.70K
    Average Volume (3 months) 3.30M
    Market Cap 15.57M
    P/E Ratio -100.00K
    Shares Outstanding 29.81M
    Revenue N/A
    EPS -0.90
    Dividend (Yield %) N/A
    Beta 1.87
    Next Earnings Date Mar 20, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 1, 2023 0.57 0.01 1.79% 0.56 0.59 0.56
    Nov 30, 2023 0.56 0.00 0.00% 0.56 0.58 0.56
    Nov 29, 2023 0.56 0.00 0.00% 0.56 0.56 0.55
    Nov 28, 2023 0.55 0.00 0.00% 0.55 0.57 0.53
    Nov 27, 2023 0.53 -0.02 -3.64% 0.55 0.56 0.52
    Nov 24, 2023 0.56 0.04 7.69% 0.52 0.56 0.51
    Nov 22, 2023 0.52 -0.01 -1.89% 0.53 0.53 0.51
    Nov 21, 2023 0.50 -0.01 -1.96% 0.51 0.53 0.50
    Nov 20, 2023 0.51 -0.04 -7.27% 0.55 0.57 0.51
    Nov 17, 2023 0.57 -0.01 -1.72% 0.58 0.60 0.52
    Nov 16, 2023 0.58 0.03 5.45% 0.55 0.59 0.54
    Nov 15, 2023 0.55 0.03 5.77% 0.52 0.56 0.51
    Nov 14, 2023 0.53 -0.01 -1.85% 0.54 0.56 0.50
    Nov 13, 2023 0.55 -0.02 -3.51% 0.57 0.62 0.53
    Nov 10, 2023 0.52 0.03 6.12% 0.49 0.52 0.48
    Nov 9, 2023 0.49 -0.02 -3.92% 0.51 0.52 0.45
    Nov 8, 2023 0.53 -0.01 -1.85% 0.54 0.54 0.52
    Nov 7, 2023 0.53 -0.03 -5.36% 0.56 0.56 0.53
    Nov 6, 2023 0.57 0.05 9.62% 0.52 0.57 0.52
    Nov 3, 2023 0.49 0.02 4.26% 0.47 0.49 0.47

    Moleculin Biotech, Inc. Events

    Time (UTC) Country Event
    Wednesday, March 20, 2024

    Time (UTC)

    20:00

    Country

    US

    Event

    Q4 2023 Moleculin Biotech Inc Earnings Release
    Q4 2023 Moleculin Biotech Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0 0 0 0 0
    Revenue 0 0 0 0 0
    Total Operating Expense 30.64 22.968 19.742 17.524 15.025
    Selling/General/Admin. Expenses, Total 11.542 8.386 6.785 6.312 5.229
    Research & Development 18.968 14.418 12.757 11.013 9.728
    Depreciation / Amortization 0.13 0.164 0.2 0.199 0.068
    Operating Income -30.64 -22.968 -19.742 -17.524 -15.025
    Interest Income (Expense), Net Non-Operating 1.575 7.034 2.359 4.075 3.189
    Net Income Before Taxes -29.025 -15.894 -17.355 -13.434 -11.876
    Net Income After Taxes -29.025 -15.894 -17.355 -13.205 -11.876
    Net Income Before Extra. Items -29.025 -15.894 -17.355 -13.205 -11.876
    Net Income -29.025 -15.894 -17.355 -13.205 -11.876
    Income Available to Common Excl. Extra. Items -29.025 -15.894 -17.355 -13.205 -11.876
    Income Available to Common Incl. Extra. Items -29.025 -15.894 -17.355 -13.205 -11.876
    Diluted Net Income -29.025 -15.894 -17.355 -13.205 -11.876
    Diluted Weighted Average Shares 28.6044 26.8759 9.84569 6.78704 4.31745
    Diluted EPS Excluding Extraordinary Items -1.0147 -0.59138 -1.7627 -1.94562 -2.7507
    Diluted Normalized EPS -1.0147 -0.59138 -1.7627 -1.94562 -2.7507
    Unusual Expense (Income) 0
    Other, Net 0.04 0.04 0.028 0.015 -0.04
    Total Extraordinary Items
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0 0 0 0 0
    Revenue 0 0 0 0 0
    Total Operating Expense 6.411 8.354 7.048 9.084 7.434
    Selling/General/Admin. Expenses, Total 2.492 2.637 2.838 3.087 3.196
    Research & Development 3.888 5.687 4.178 5.965 4.204
    Depreciation / Amortization 0.031 0.03 0.032 0.032 0.034
    Operating Income -6.411 -8.354 -7.048 -9.084 -7.434
    Interest Income (Expense), Net Non-Operating 0.426 0.431 0.277 0.454 0.642
    Other, Net 0.009 0.008 0.001 0.019 0.015
    Net Income Before Taxes -5.976 -7.915 -6.77 -8.611 -6.777
    Net Income After Taxes -5.976 -7.915 -6.77 -8.611 -6.777
    Net Income Before Extra. Items -5.976 -7.915 -6.77 -8.611 -6.777
    Net Income -5.976 -7.915 -6.77 -8.611 -6.777
    Income Available to Common Excl. Extra. Items -5.976 -7.915 -6.77 -8.611 -6.777
    Income Available to Common Incl. Extra. Items -5.976 -7.915 -6.77 -8.611 -6.777
    Diluted Net Income -5.976 -7.915 -6.77 -8.611 -6.777
    Diluted Weighted Average Shares 29.6889 28.75 28.6281 28.6276 28.583
    Diluted EPS Excluding Extraordinary Items -0.20129 -0.2753 -0.23648 -0.30079 -0.2371
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.20129 -0.2753 -0.23648 -0.30079 -0.2371
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 45.596 72.497 17.198 13.484 7.974
    Cash and Short Term Investments 43.145 70.903 15.173 10.735 7.134
    Cash & Equivalents 43.145 70.903 15.173 10.735 7.134
    Prepaid Expenses 1.401 1.075 1.86 2.209 0.84
    Total Assets 57.422 84.09 29.031 25.235 19.585
    Property/Plant/Equipment, Total - Net 0.678 0.445 0.685 0.603 0.463
    Property/Plant/Equipment, Total - Gross 0.976 0.957 0.6 0.556
    Accumulated Depreciation, Total -0.638 -0.474 -0.284 -0.093
    Intangibles, Net 11.148 11.148 11.148 11.148 11.148
    Total Current Liabilities 4.819 3.622 2.92 3.57 3.878
    Payable/Accrued
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases
    Total Liabilities 5.231 5.097 11.271 9.664 5.313
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 0.412 1.475 8.351 6.094 1.435
    Total Equity 52.191 78.993 17.76 15.571 14.272
    Common Stock 0.029 0.029 0.069 0.046 0.029
    Additional Paid-In Capital 153.985 151.733 74.671 55.055 40.564
    Retained Earnings (Accumulated Deficit) -101.835 -72.81 -56.916 -39.561 -26.356
    Other Equity, Total 0.012 0.041 -0.064 0.031 0.035
    Total Liabilities & Shareholders’ Equity 57.422 84.09 29.031 25.235 19.585
    Total Common Shares Outstanding 28.6278 28.5783 11.5367 7.62144 4.75487
    Accounts Payable 2.095 1.364 1.129 2.153 1.246
    Accrued Expenses 2.638 2.149 1.713 1.318 2.302
    Other Current Liabilities, Total 0.086 0.109 0.078 0.099 0.33
    Preferred Stock - Non Redeemable, Net 0 0 0 0 0
    Total Receivables, Net 1.048 0.496 0.164 0.011
    Other Current Assets, Total 0.002 0.023 0.001 0.529
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 27.603 35.38 39.289 45.596 53.493
    Cash and Short Term Investments 24.579 32.172 37.265 43.145 50.392
    Cash & Equivalents 24.579 32.172 37.265 43.145 50.392
    Prepaid Expenses 3.024 1.976 2.024 1.401 1.745
    Total Assets 39.523 47.115 51.062 57.422 65.372
    Property/Plant/Equipment, Total - Net 0.772 0.587 0.625 0.678 0.731
    Intangibles, Net 11.148 11.148 11.148 11.148 11.148
    Total Current Liabilities 3.888 6.554 5.032 4.819 6.362
    Accounts Payable 2.008 4.136 1.939 2.095 3.568
    Accrued Expenses 1.815 2.418 3.093 2.638 2.684
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 0.065 0.086 0.11
    Total Liabilities 4.385 6.847 5.378 5.231 6.955
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 0.497 0.293 0.346 0.412 0.593
    Total Equity 35.138 40.268 45.684 52.191 58.417
    Preferred Stock - Non Redeemable, Net 0 0 0 0 0
    Common Stock 0.03 0.03 0.03 0.029 0.029
    Additional Paid-In Capital 156.446 155.957 155.396 153.985 153.45
    Retained Earnings (Accumulated Deficit) -121.335 -115.726 -109.75 -101.835 -95.065
    Other Equity, Total -0.003 0.007 0.008 0.012 0.003
    Total Liabilities & Shareholders’ Equity 39.523 47.115 51.062 57.422 65.372
    Total Common Shares Outstanding 29.8104 29.7893 29.6003 28.6278 28.6278
    Total Receivables, Net 1.225 1.048 1.35
    Other Current Assets, Total 0.007 0.002 0.006
    Property/Plant/Equipment, Total - Gross 1.044
    Accumulated Depreciation, Total -0.769
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -29.025 -15.894 -17.355 -13.205 -11.876
    Cash From Operating Activities -27.639 -18.951 -17.771 -17.198 -12.203
    Cash From Operating Activities 0.13 0.164 0.2 0.199 0.068
    Non-Cash Items 1.032 -4.259 -0.575 -2.05 -2.005
    Cash Taxes Paid 0.015 0.024 0.019 0
    Cash Interest Paid 0 0 0.001 0.005
    Changes in Working Capital 0.224 1.038 -0.041 -2.142 1.61
    Cash From Investing Activities -0.067 -0.019 -0.374 -0.051 -0.417
    Capital Expenditures -0.067 -0.019 -0.376 -0.052 -0.417
    Other Investing Cash Flow Items, Total 0 0.002 0.001
    Cash From Financing Activities -0.023 74.724 22.549 20.854 12.045
    Issuance (Retirement) of Stock, Net 0 74.747 22.566 20.854 12.045
    Issuance (Retirement) of Debt, Net
    Net Change in Cash -27.758 55.73 4.438 3.601 -0.58
    Foreign Exchange Effects -0.029 -0.024 0.034 -0.004 -0.005
    Financing Cash Flow Items -0.023 -0.023 -0.017
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -7.915 -29.025 -22.255 -13.644 -6.867
    Cash From Operating Activities -6.017 -27.639 -20.383 -12.806 -4.805
    Cash From Operating Activities 0.03 0.13 0.098 0.066 0.032
    Non-Cash Items 1.342 1.032 0.652 0.362 0.457
    Cash Taxes Paid 0.109
    Changes in Working Capital 0.526 0.224 1.122 0.41 1.573
    Cash From Investing Activities 0 -0.067 -0.067 -0.067 -0.006
    Capital Expenditures 0 -0.067 -0.067 -0.067 -0.006
    Cash From Financing Activities 0.141 -0.023 -0.023 -0.012 0
    Issuance (Retirement) of Stock, Net 0.141 0 0 0 0
    Foreign Exchange Effects -0.004 -0.029 -0.038 -0.019 0.012
    Net Change in Cash -5.88 -27.758 -20.511 -12.904 -4.799
    Financing Cash Flow Items -0.023 -0.023 -0.012
    Other Investing Cash Flow Items, Total
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 3.6233 1080122 0 2023-06-30 LOW
    Klemp Walter V Individual Investor 1.652 492476 21121 2023-07-11 LOW
    Sio Capital Management, LLC Hedge Fund 1.0177 303389 -707567 2023-06-30 HIGH
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.8267 246451 0 2023-06-30 LOW
    AnnaMed, Inc. Corporation 0.8001 238500 0 2023-03-27 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 0.6581 196196 -57298 2023-06-30 LOW
    Renaissance Technologies LLC Hedge Fund 0.4274 127400 32795 2023-06-30 HIGH
    IntertechBio Corporation Corporation 0.3522 105000 0 2023-03-27 LOW
    Picker (Donald H) Individual Investor 0.3019 90006 11900 2023-06-20 LOW
    Squarepoint Capital LLP Investment Advisor/Hedge Fund 0.2591 77238 53298 2023-06-30 LOW
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.2395 71397 0 2023-06-30 LOW
    Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.1798 53596 0 2023-06-30 LOW
    Foster (Jonathan P.) Individual Investor 0.1413 42114 40447 2023-06-20 LOW
    Millennium Management LLC Hedge Fund 0.1132 33741 33741 2023-06-30 HIGH
    P. J. Schmidt Investment Management, Inc. Investment Advisor 0.0973 29000 0 2023-09-30 LOW
    Sigma Planning Corporation Investment Advisor 0.057 17000 -40500 2023-06-30 LOW
    Tower Research Capital LLC Hedge Fund 0.0482 14374 2045 2023-06-30 HIGH
    JMAC Enterprises LLC Investment Advisor 0.0441 13132 0 2023-09-30 LOW
    Two Sigma Investments, LP Hedge Fund 0.044 13115 -406 2023-06-30 HIGH
    Morgan Stanley & Co. LLC Research Firm 0.0201 6000 0 2023-06-30 MED

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Moleculin Biotech, Inc. Company profile

    About Moleculin Biotech Inc

    Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the treatment of resistant cancers and viruses through the development of its drug candidates. The Company has three product pipelines: Annamycin, WP1066 and WP1122. Annamycin is developed for the treatment of relapsed or refractory acute myeloid leukemia (AML). WP1066 is a immune or transcription modulators capable of stimulating immune response to tumors by inhibiting the errant activity of Regulatory T-Cells (TRegs) while also inhibiting key oncogenic transcription factors, including p-STAT3, c-Myc and HIF-1α. WP1122 is a prodrug of 2-deoxy-D-glucose (2-DG), which provides an opportunity to cut off the fuel supply of tumors by taking advantage of their overdependence on glucose as compared with healthy cells.

    Financial summary

    BRIEF: For the nine months ended 30 September 2021, Moleculin Biotech Inc revenues was not reported. Net loss decreased 11% to $13.1M. Lower net loss reflects Gain from change in fair value of warran increase from $1.5M to $4.4M (income), Research and development balancing value decrease of 2% to $10.5M (expense), Interest Income, Net increase from $10K to $236K (income).

    Industry: Pharmaceuticals (NEC)

    5300 Memorial Dr Ste 950
    HOUSTON
    TEXAS 77007
    US

    Income Statement

    • Annual
    • Quarterly

    News

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023
    GBP

    UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

    UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

    10:48, 21 November 2023

    People also watch

    Gold

    2,072.25 Price
    +1.760% 1D Chg, %
    Long position overnight fee -0.0193%
    Short position overnight fee 0.0111%
    Overnight fee time 22:00 (UTC)
    Spread 0.30

    US100

    16,001.20 Price
    +0.470% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 7.0

    Oil - Crude

    74.50 Price
    -1.560% 1D Chg, %
    Long position overnight fee -0.0136%
    Short position overnight fee -0.0083%
    Overnight fee time 22:00 (UTC)
    Spread 0.040

    XRP/USD

    0.63 Price
    -0.120% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading